Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda as salvage therapy in multiple myeloma after CAR-T
NCT05204160Phase 2Withdrawn
- Sponsor
- Emory University
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by Emory University. Planned start Apr 2022; status: withdrawn.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05204160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05204160.